CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年3月30日～2025年4月5日の間に収集した論文情報を追加しました。

  1. A retrospective research of adverse event reporting system events for voxelotor based on the FAERS database.

  ボクセロトールの副作用には未記載のものもあり、長期的な安全性監視が必要

  対象DB：FAERS

  2. Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system.

  タイプIb MET TKIの安全性に違いがあり、製品ラベル更新が必要

  対象DB：FAERS

  3. Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis.

  免疫チェックポイント阻害薬による膵炎のリスクが確認され、治療にはステロイドが推奨される

  対象DB：FAERS

  4. The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases.

  アザシチジンの副作用として新たな懸念が確認され、安全性情報提供

  対象DB：FAERS

  5. Real-world data analysis of topotecan in combination with Bevacizumab or CycloPhosphamide in the FDA adverse event reporting system (FAERS) database.

  トポテカン、ベバシズマブ、シクロホスファミドの併用で新たな副作用発見

  対象DB：FAERS

  6. Analysis of diroximel fumarate data for patients with relapsing forms of multiple sclerosis using related adverse events from the FDA adverse reporting system.

  DRF治療に新たな副作用シグナルを確認

  対象DB：FAERS

  7. Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database.

  エテルカルセチド治療における新たな副作用シグナルを発見

  対象DB：FAERS

  8. A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system.

  アデュカヌマブの主要な安全性リスクはARIA関連のイベントであり、特に75歳以上で顕著

  対象DB：FAERS

  9. A real-world disproportionality analysis of ripretinib data mining of the public version of FDA adverse event reporting system.

  リプレチニブ関連の新たな副作用が確認され、さらなる研究が必要

  対象DB：FAERS

  10. Exploring the Relationship Between Antipsychotic Drug Target Genes and Epilepsy: Evidence From Food and Drug Administration Adverse Event Reporting System Database and Mendelian Randomization.

  抗精神病薬はてんかん関連の副作用を引き起こす可能性あり

  対象DB：FAERS

  11. Analysis of Adverse Events Associated With Dental Local Anaesthetics Using Food and Drug Administration Adverse Event Reporting System Data.

  エステル型局所麻酔薬は重篤な副作用が高い

  対象DB：FAERS

  12. Sedatives and Opioids Best Practices: An Approach to the Use of Technological Tools.

  集中治療医が鎮静薬・オピオイドの管理に技術ツールの必要性を認識

  対象DB：FAERS

  13. Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study.

  乳がん治療薬でILD報告が増加、年齢と体重が関連

  対象DB：FAERS,JADER

  14. Enhancing Relation Extraction for COVID-19 Vaccine Shot-Adverse Event Associations with Large Language Models.

  COVID-19ワクチンと副作用の関係を抽出、精度94%

  対象DB：FAERS,VAERS

  15. Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).

  メラズマは薬剤使用と関連し、避妊薬が強い関連を示す

  対象DB：FAERS

  16. Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data.

  ロチゴチンは予期しない深刻な副作用を示す

  対象DB：FAERS

  17. A disproportionality analysis of hydrocortisone-related adverse Events:A real-world pharmacovigilance study using the FAERS Database.

  ヒドロコルチゾンは内分泌障害や免疫系障害と関連

  対象DB：FAERS

  18. Adverse events associated with obeticholic acid: a real-world, pharmacovigilance study.

  OCAの安全性に関する重要なリスクはかゆみと肝障害

  対象DB：FAERS

  19. Adverse drug reactions linked to fidaxomicin: insights from a retrospective analysis of the FAERS database.

  フィダキソマイシンは一般的に良好であるが、重篤な神経精神科的副作用が報告

  対象DB：FAERS

  20. Exploring Associations Between COVID-19 Bivalent Vaccines and Their Related Adverse Events: A Correlational Study.

  COVID-19二価ワクチンの副作用は、年齢、性別、ワクチンによって異なる

  対象DB：FAERS,VAERS

  21. Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system.

  セレコキシブは神経疾患や癌で予期せぬ副作用が確認

  対象DB：FAERS

  22. Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system.

  メトロニダゾールはCNS障害と関連し、クロナゼパムが抑制効果を示唆

  対象DB：FAERS,JADER

  23. Disproportionality analysis of BRAF and MEK inhibitors demonstrate risk of retinal detachment: an analysis of the FDA Adverse Event Reporting System.

  BRAFおよびMEK阻害薬の使用で網膜剥離リスク

  対象DB：FAERS

  24. Potential drugs associated with toxic epidermal necrolysis: a disproportionality analysis based on the FAERS database (2004-2024).

  薬剤性TENのリスク薬特定、早期対応に有用

  対象DB：FAERS

  25. Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system.

  S1PR修飾薬により心血管イベントのリスクが増加

  対象DB：FAERS

  26. Risk factors for clazosentan-induced fluid retention in subarachnoid hemorrhage from the Japanese adverse event database.

  高齢者とファスジル併用がクレゾセンタンによる浮腫のリスク因子

  対象DB：JADER

  27. Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database.

  セマグルチドは自殺念慮、脱毛と関連

  対象DB：VigiBase

  28. Quality indicators for endometrial cancer care in Japan.

  子宮体癌治療のQIsを開発。HRTの遵守率が低い

  対象DB：DPC

  29. Assessment of incidence and risk factors of COVID-19-associated candidemia using diagnosis procedure combination data.

  COVID-19重症患者でのカンジダ血症は死亡リスクを高める

  対象DB：DPC

  30. Clinical burden of late-onset, clinically significant CMV infection beyond 100 days in allo-HSCT patients after letermovir prophylaxis.

  遅発性CMViは移植後100日以降に高リスク患者で多発

  対象DB：JMDC

  31. Annual Trend of Myopia and High Myopia in Children in Japan: A Nationwide Claims Database Study.

  近視の発症率は8歳でピーク、コロナ禍で増加

  対象DB：NDB

  32. Status of Diagnostic Test, Diagnosis, and Treatment of Influenza Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

  日本の保険データでインフル診断と抗ウイルス薬処方が確認された

  対象DB：NDB

  33. Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan.

  JIA治療でTCZ皮下注の適応拡大が最優先課題

  対象DB：NDB

  34. Real-world use of BTK inhibitors for chronic lymphocytic leukemia in Japan: A retrospective observational database study.

  日本のCLL治療でBTKiの減量・中止が多い

  対象DB：MDV

  35. Capturing the human impact of living with multiple long-term conditions in routine electronic health records - lost in translation?

  EHRには患者中心の負担が反映不足

  対象DB：CPRD

  36. Co-prescription of metformin and antipsychotics in severe mental illness: a UK primary care cohort study.

  メトホルミン併用で体重増加が軽減

  対象DB：CPRD

  37. Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy.

  妊娠高血圧はDCMリスクを有意に増加

  対象DB：CPRD

  38. Incidence and survival of colorectal cancer in the United Kingdom from 2000-2021: a population-based cohort study.

  若年発症が増加、全体生存率は緩やかに改善

  対象DB：CPRD

  39. Optimal risk assessment intervals for primary prevention of cardiovascular disease: a population-based two-stage landmarking study.

  性別・初期リスク・年齢で頻度調整推奨

  対象DB：CPRD

  40. Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom population (ACEL-UK): Cohort Study.

  LT4治療は心血管に有益だが骨折増加

  対象DB：THIN

  41. All-cause healthcare resource utilization and costs among community-managed adults with long-COVID in France, 2020-2023.

  Long COVIDは医療費増大と資源負担を伴う

  対象DB：THIN

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み